News

As of July 15, 2015, the latest overall survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the HEAT Study patients),

PH1 is a severe, rare, inherited disorder of the liver that often results in kidney failure and for which there are no approved therapies. Orphan Drug Designation by

"ATryn, an innovative treatment for patients with hereditary antithrombin deficiency, marks Knight’s first submission to Health Canada", said Jonathan Ross Goodman, President and CEO of Knight. "ATryn is

The objective is to optimize Fc receptor mediated antibody function. The work will be conducted in the Laboratory of Molecular Genetics and Immunology at The Rockefeller University, which

As part of the deal, HCI awarded LSKB global rights in all therapeutic indications of HCI-1401. Developed by HCI’s Center for investigational therapeutics, HCI-1401 was selectively designed to

To be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center, the Phase II trial will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients

TD-8954 is being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Currently, TD-8954 is in Phase II clinical development having

Breo Ellipta is a fixed-dose combination (FDC) of the inhaled corticosteroid (ICS) fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol. In Canada two strengths 100/25mcg and 200/25mcg of

Additionally, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE,